Blood cancer starts when a single blood cell or blood-forming cell picks up a DNA mutation that makes it multiply out of control. Unlike solid tumors that form a lump in one organ, blood cancers take over the factory where blood is made (bone marrow), the drainage network of your immune system (lymph nodes), or both. The result is the same across all types: abnormal cells crowd out the healthy ones your body depends on, and your blood gradually loses its ability to do its job.
Where Blood Cells Come From
To understand blood cancer, you need a quick picture of normal blood production. Your bone marrow, the spongy tissue inside large bones, constantly produces three types of cells. Red blood cells carry oxygen to every tissue in your body, supplying your cells with energy. White blood cells patrol for bacteria, viruses, fungi, and other threats. Platelets cause your blood to clot and prevent excessive bleeding. All three start as immature “blast” cells in the marrow, then mature and enter the bloodstream when they’re ready to work.
Blood cancer disrupts this assembly line at different points depending on the type. Some cancers hijack the earliest blast cells. Others corrupt cells that have already partially matured. But the core problem is always a DNA error that tells a cell to keep dividing when it should stop, or to survive when it should die.
The Three Main Types
Leukemia: Cancer in the Bone Marrow
Leukemia begins in the bone marrow itself. A blast cell acquires a mutation, then divides rapidly and makes copies of itself that are too immature and abnormal to serve any useful purpose. These defective cells take up so much space inside the marrow that they physically prevent the production of new, healthy blood cells. The marrow becomes like a parking lot jammed with broken-down cars: nothing functional can get through.
One well-studied trigger is a genetic accident called the Philadelphia chromosome. Pieces of chromosomes 9 and 22 break off and swap places, fusing two genes that don’t belong together. The merged gene produces an abnormal protein that forces certain marrow cells to churn out huge numbers of defective white blood cells. These cells don’t protect you from infections the way healthy white blood cells do. They simply pile up in the blood and marrow, crowding out everything else. This particular mutation drives one form of leukemia, but the general pattern (a genetic error that jams the accelerator on cell growth) applies across many subtypes.
Lymphoma: Cancer in the Lymph Nodes
Lymphoma targets a specific white blood cell called a lymphocyte, the type responsible for recognizing and remembering infections. When lymphocytes pick up DNA mutations, they grow out of control and live longer than they should, continuing to multiply and produce more diseased cells. These abnormal lymphocytes accumulate in the lymph nodes, the small filtering stations spread throughout your body, and form tumors that crowd out healthy tissue and limit its ability to function.
Because lymph nodes exist everywhere, from your neck and armpits to your chest and abdomen, lymphoma can show up in many locations at once. The swollen, painless lumps people sometimes notice are actually lymph nodes packed with cancerous cells.
Myeloma: Cancer in Plasma Cells
Multiple myeloma starts in plasma cells, a specialized type of white blood cell that normally produces antibodies to fight infection. Cancerous plasma cells produce excess amounts of a single, identical abnormal protein instead of the diverse mix of antibodies your immune system needs. As these malignant cells multiply, they suppress the production of normal antibodies, leaving you increasingly vulnerable to infections.
Myeloma also attacks bone. The cancerous plasma cells cluster inside the bone marrow and trigger bone breakdown, which can cause bone pain, fractures, and visible holes called bone lesions on imaging scans. In advanced cases, the flood of abnormal protein can damage the kidneys as well.
How Crowding Creates Symptoms
No matter which type of blood cancer is involved, the downstream effects follow a predictable pattern tied to which healthy cells get squeezed out.
- Too few red blood cells (anemia): Less oxygen reaches your tissues, so you feel persistent weakness and fatigue that rest doesn’t fix.
- Too few functional white blood cells: Your immune system can’t fight off everyday pathogens, leading to frequent or stubborn infections.
- Too few platelets: Your blood can’t clot properly. You may bruise easily, bleed from minor cuts longer than expected, or notice tiny reddish-purple dots on your skin called petechiae, which are spots of bleeding just beneath the surface.
These three problems often appear together, and they tend to worsen gradually as the cancer expands. Many people first visit a doctor because of unexplained fatigue or an infection that won’t clear, not suspecting a blood cancer is behind it.
What Goes Wrong at the DNA Level
Blood cancers are almost always caused by acquired mutations, meaning they aren’t inherited from your parents but develop after birth when cells make a copying error during division, or when DNA is damaged by exposure to cancer-causing substances. One cell gets a mutation that gives it a growth advantage, and that cell’s descendants eventually dominate.
The Philadelphia chromosome is one of the best-understood examples. Researchers in Philadelphia discovered that chromosomes 9 and 22 swap broken-off segments, creating a fusion gene that codes for a rogue protein. That protein essentially flips a permanent “on” switch for cell production. Other blood cancers involve different mutations in different genes, but the theme is consistent: a genetic change removes the brakes on growth or blocks the signals that tell a damaged cell to self-destruct.
How Blood Cancer Is Identified
Diagnosis usually starts with a routine blood test that reveals abnormal cell counts, then moves to more specialized analysis. One key tool is flow cytometry, a technique that identifies the exact type of cell involved by checking which proteins sit on its surface. By tagging cells with markers, lab technicians can determine whether a cancer involves B cells, T cells, or myeloid cells (the lineage that produces red blood cells, platelets, and certain white blood cells). This matters because treatment strategies differ significantly depending on the cell type.
Bone marrow biopsies provide a direct look at the factory floor, showing how many blast cells are present and whether normal production has been disrupted. Genetic testing can identify specific chromosomal swaps like the Philadelphia chromosome, which sometimes opens the door to targeted treatments designed to block the exact protein driving the cancer.
When Blood Itself Becomes Dangerous
In some cases, blood cancer creates a secondary problem: the blood physically thickens. When the number of abnormal cells or abnormal proteins climbs high enough, blood doesn’t flow freely through vessels anymore, a condition called hyperviscosity syndrome. Thickened blood leads to poor circulation in the brain, causing headaches, dizziness, or confusion. Without treatment, it can block arteries and reduce blood flow to vital organs, potentially leading to organ damage. In children, reduced blood flow can even affect growth and development.
Hyperviscosity is most common in myeloma (because of the flood of abnormal protein) and in leukemias with extremely high white blood cell counts. It’s a medical emergency that requires rapid intervention to thin the blood and restore normal flow.
Survival and Outlook
Outcomes vary enormously depending on the specific type and subtype. For leukemia overall, the five-year relative survival rate is 68.6%, according to data from the National Cancer Institute covering 2016 through 2022. That number blends together both aggressive and slow-growing forms, so individual prognosis can be much better or much worse than the average. Some chronic leukemias are managed for decades as a chronic condition, while certain acute forms require intensive treatment soon after diagnosis.
Lymphoma survival rates are generally favorable for many subtypes, particularly when caught early. Myeloma remains harder to cure but has seen significant improvements in how long patients live and how well they feel during treatment. Across all blood cancers, the past two decades have brought targeted therapies that go after specific mutations, which has steadily pushed survival numbers upward.